Vitiligo, New Treatment and Serum s100B

Sponsor
South Valley University
Study ID
NCT06768840
Phase
PHASE2/PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Vitiligo, Generalized

Eligibility Criteria

Sex
ALL
Age
10 Years - 75 Years
Healthy Volunteers
Accepted

Interventions

  • Baricitinib — DRUG
    oral baricitinib 4mg for adults and 2mg for children 10-16 years for group A
  • oral mini pulse — DRUG
    pulse dose of oral dexamethasone 2.5mg for adults for two consecutive days per week and half the dose for children
  • Narrow Band UVB Treatment — RADIATION
    narrowband ultraviolet rays B phototherapy two sessions per week

Study Details

vitiligo is an autoimmune depigmenting skin disorder characterized by milky white macules or patches, with 2% worldwide prevalence. Vitiligo has unexpected course that significantly influences on patient's quality of life and self-esteem. Multiple medications have been introduced for vitiligo treatment, in this study we work on one of systemic JAK inhibitors

Key Dates

Start date
Oct 2, 2024
Status verified
Jan 2025
Primary completion
Aug 31, 2025
Completion
Oct 31, 2025

Study Design

Enrollment
50 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: baricitinib
    group A, vitiligo patients will receive oral baricitinib plus narrow band ultraviolet rays B phototherapy for 3 to 6 months and serum s100B will be measured before the start of the treatment and after three months of the treatment.
  • No Intervention: control
    healthy matched controls for them serum s100B will be measured
  • Active Comparator: oral mini pulse
    vitiligo patients will recieve oral mini pulse therapy plus phototherapy for three to six months ,serum s100B will be measured before and three months after start of the treatment.

Primary Outcome Measure

serum s100B in active generalized vitiligo [ Time Frame: at the time of enrollment ]

Central Contacts